A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone

SCHIZOPHRENIA RESEARCH

卷:204

Article

Robinson, Delbert G.^1,2,3  Gallego, Juan A.^1,2,3,6  John, Majnu^2,3,4  Hanna, Lauren A.³  Zhang, Jian-Ping^1,2,3  Birnbaum, Michael L.^1,2,3  Greenberg, Jessica^3,7  Naraine, Melissa^3,7  Peters, Bart D.^3,8  McNamara, Robert K.⁵  Malhotra, Anil K.^1,2,3  Szeszko, Philip R.^1,2,3,9,10 

[1] Donald & Barbara Zucker Sch Med Hofstra Northwell, Hemstead, NY USA

[2] Feinstein Inst Med Res, Manhasset, NY USA

[3] Zucker Hillside Hosp, Glen Oaks, NY 11004 USA

[4] Hofstra Univ, Hempstead, NY 11550 USA

[5] Univ Cincinnati, Coll Med, Cincinnati, OH USA

[6] Weill Cornell Med Coll, New York Presbyterian Westchester Div, White Plains, NY USA

[7] Vanguard Res Gmup, Glen Oaks, NY USA

[8] Vrije Univ Amsterdam Med Ctr, Dept Child & Adolescent Psychiat, Amsterdam, Netherlands

[9] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[10] James J Peters VA Med Ctr, Bronx, NY USA

关键词: Omega-3;    Recent onset psychosis;    Risperidone;    Adjuvant treatment;    Depression;    Anxiety;   

DOI  :  10.1016/j.schres.2018.09.006

来源: Elsevier

【 摘 要 】

Omega-3 treatment studies for multi-episode schizophrenia or clinical high risk for conversion to psychosis states have had variable, and often negative, results. To examine adjunctive omega-3 treatment for recent onset psychosis, participants aged 15-40 years with recent onset schizophrenia-spectrum (n = 46) or bipolar (n = 4) disorders and current psychotic symptoms were treated for 16 weeks with risperidone and randomly-assigned omega-3 (EPA 740 mg and DHA 400 mg daily) or matching placebo. The primary outcome measure was the Brief Psychiatric Rating Scale (BPRS) total score. Mean lifetime antipsychotic exposure was 18.1 days. Length of time in treatment, risperidone dose and number of omega-3/placebo capsules taken did not differ between conditions. Longitudinal analysis of the total BPRS score revealed a trend level (p = 0.0826) treatment effect favoring omega-3 treatment. Lorazepam was an allowed concomitant medication. Among the subgroup (N = 23) who did not receive lorazepam, the treatment effect on BPRS total scores favoring omega-3 was significant (p = 0.0406) and factor scores analyses revealed a substantial decrease in depression-anxiety with omega-3 but no change with placebo (treatment-by-time interaction. p = 0.0184). Motor side effects did not differ between conditions. Analysis of Systematic Assessment for Treatment Emergent Events assessments revealed fewer adverse events overall with omega-3 compared with placebo with the largest differences between conditions (all favoring omega-3) on confusion, anxiety, depression, irritability, and tiredness/fatigue. These results suggest that omega-3 adjuvant treatment is a potential option for depression and anxiety symptoms of people with recent onset psychosis. Further research is needed to confirm this potential. (C) 2018 Elsevier B.V. All rights reserved.

【 授权许可】

Free